Marcio Souza, Praxis Precision Medicines CEO
January 11, 2024 11:32 AM EST
Financing

Prax­is prices $150M pub­lic stock of­fer­ing ahead of four topline neu­ro read­outs in 2024

Katherine Lewin

News Reporter

Boston-based Prax­is Pre­ci­sion Med­i­cines an­nounced Thurs­day the pric­ing of a $150 mil­lion pub­lic stock of­fer­ing, with an ex­pect­ed close date around …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Bridge­Bio shares promis­ing re­sults in tri­al of Cana­van dis­ease gene ther­a­py

CRISPR ther­a­py re­duces swelling at­tacks by 81% in In­tel­lia fol­low-up study

Fac­ing lost re­bates, MGM Re­sorts to stop cov­er­ing GLP-1 weight loss shots

Ex­clu­sive: Uni­ver­si­ty of Toron­to spin­out rais­es $53.5M to cre­ate new obe­si­ty drugs with AI

Icon's quar­ter­ly earn­ings hit by biotech and phar­ma pull­back

sponsored

IDEAYA Bio­sciences: Tar­get­ing un­met mar­ket needs with pre­ci­sion on­col­o­gy

A service from the Financial Times